Collins Helen Louise

CHIEF MEDICAL OFFICEREnliven Therapeutics, Inc. (ELVN) · full profile →Form 4 · filed Jun 22, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$219K
Net Open-Market Flow
-$219K
Transactions
5
4 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 17, 2026Option exercise(M)5K$2.48$12K30K
Jun 17, 2026Sell(S)1K$42.83$54K29K
Jun 17, 2026Sell(S)3K$43.87$114K26K
Jun 17, 2026Sell(S)1K$44.74$51K25K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 17, 2026Option exercise(M)5K$0121K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001701247-26-000010) within minutes of acceptance. Every field above traces to the original document. Verify it directly: